{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:34:58Z","timestamp":1790400898188,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009878","name":"Regione del Veneto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["874735"],"award-info":[{"award-number":["874735"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["STARS-CoG ISS-MYTH"],"award-info":[{"award-number":["STARS-CoG ISS-MYTH"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["PRID\/SID 2020"],"award-info":[{"award-number":["PRID\/SID 2020"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["TOPP_PRIV20_01"],"award-info":[{"award-number":["TOPP_PRIV20_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["TOPP_SID19_01"],"award-info":[{"award-number":["TOPP_SID19_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Society and Wellcome Trust","award":["213494\/Z\/18\/Z"],"award-info":[{"award-number":["213494\/Z\/18\/Z"]}]},{"name":"Community Jameel and the MRC Centre for Global Infectious Disease Analysis","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The continuous emergence of SARS-CoV-2 variants of concern (VOC) with immune escape properties, such as Delta (B.1.617.2) and Omicron (B.1.1.529), questions the extent of the antibody-mediated protection against the virus. Here we investigated the long-term antibody persistence in previously infected subjects and the extent of the antibody-mediated protection against B.1, B.1.617.2 and BA.1 variants in unvaccinated subjects previously infected, vaccinated na\u00efve and vaccinated previously infected subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood samples collected 15 months post-infection from unvaccinated (<jats:italic>n<\/jats:italic>=35) and vaccinated (<jats:italic>n<\/jats:italic>=41) previously infected subjects (Vo\u2019 cohort) were tested for the presence of antibodies against the SARS-CoV-2 spike (S) and nucleocapsid (N) antigens using the Abbott, DiaSorin, and Roche immunoassays. The serum neutralising reactivity was assessed against B.1, B.1.617.2 (Delta), and BA.1 (Omicron) SARS-CoV-2 strains through micro-neutralisation. The antibody titres were compared to those from previous timepoints, performed at 2- and 9-months post-infection on the same individuals. Two groups of na\u00efve subjects were used as controls, one from the same cohort (unvaccinated <jats:italic>n<\/jats:italic>=29 and vaccinated <jats:italic>n<\/jats:italic>=20) and a group of vaccinated na\u00efve healthcare workers (<jats:italic>n<\/jats:italic>=61).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We report on the results of the third serosurvey run in the Vo\u2019 cohort. With respect to the 9-month time point, antibodies against the S antigen significantly decreased (<jats:italic>P<\/jats:italic>=0.0063) among unvaccinated subjects and increased (<jats:italic>P<\/jats:italic>&lt;0.0001) in vaccinated individuals, whereas those against the N antigen decreased in the whole cohort. When compared with control groups (na\u00efve Vo\u2019 inhabitants and na\u00efve healthcare workers), vaccinated subjects that were previously infected had higher antibody levels (<jats:italic>P<\/jats:italic>&lt;0.0001) than vaccinated na\u00efve subjects. Two doses of vaccine elicited stronger anti-S antibody response than natural infection (<jats:italic>P<\/jats:italic>&lt;0.0001). Finally, the neutralising reactivity of sera against B.1.617.2 and BA.1 was 4-fold and 16-fold lower than the reactivity observed against the original B.1 strain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results confirm that vaccination induces strong antibody response in most individuals, and even stronger in previously infected subjects. Neutralising reactivity elicited by natural infection followed by vaccination is increasingly weakened by the recent emergence of VOCs. While immunity is not completely compromised, a change in vaccine development may be required going forward, to generate cross-protective pan-coronavirus immunity in the global population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13073-022-01066-2","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:04:56Z","timestamp":1654855496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-8356","authenticated-orcid":false,"given":"Enrico","family":"Lavezzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Pacenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Manuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Boldrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Cattai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caldart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioele","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nieddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Salvadoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Labella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Vanuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela Ileana","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Plebani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra R.","family":"Brazzale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Toppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Dorigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Crisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"12","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"e0244126","DOI":"10.1371\/journal.pone.0244126","volume":"15","author":"N Post","year":"2020","unstructured":"Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLOS One. 2020;15(12).","journal-title":"PLOS One."},{"key":"1066_CR2","unstructured":"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study - The Lancet Microbe [Internet]. [cited 2021 Oct 23]. Available from: https:\/\/www.thelancet.com\/journals\/lanmic\/article\/PIIS2666-5247(20)30120-8\/fulltext."},{"issue":"1","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41467-021-22034-1","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12(1):1813.","journal-title":"Nat Commun."},{"issue":"15","key":"1066_CR4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1001\/jama.2021.15125","volume":"326","author":"D Steensels","year":"2021","unstructured":"Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533\u20135.","journal-title":"JAMA."},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","volume":"6","author":"P Naaber","year":"2021","unstructured":"Naaber P, Tserel L, Kangro K, Sepp E, J\u00fcrjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health - Eur. 2021;6:100208.","journal-title":"Lancet Reg Health - Eur."},{"issue":"10249","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467\u201378.","journal-title":"The Lancet."},{"key":"1066_CR7","unstructured":"Self WH. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions \u2014 United States, March\u2013August 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Oct 23];70. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7038e1.htm."},{"issue":"1","key":"1066_CR8","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1038\/s41467-021-24622-7","volume":"12","author":"I Dorigatti","year":"2021","unstructured":"Dorigatti I, Lavezzo E, Manuto L, Ciavarella C, Pacenti M, Boldrin C, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo\u2019. Nat Commun. 2021;12(1):4383.","journal-title":"Nat Commun."},{"key":"1066_CR9","doi-asserted-by":"crossref","unstructured":"Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14(637):eabn8057.","DOI":"10.1126\/scitranslmed.abn8057"},{"key":"1066_CR10","doi-asserted-by":"crossref","unstructured":"Wu J, Liang BY, Fang YH, Wang H, Yang XL, Shen S, et al. Occurrence of COVID-19 symptoms during SARS-CoV-2 infection defines waning of humoral immunity. Front Immunol. 2021;12 [cited 2022 Apr 13]. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2021.722027.","DOI":"10.3389\/fimmu.2021.722027"},{"issue":"6","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","volume":"2","author":"WN Chia","year":"2021","unstructured":"Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Bert NL, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240\u20139.","journal-title":"Lancet Microbe."},{"issue":"7851","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639\u201344.","journal-title":"Nature."},{"issue":"10283","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459\u201369.","journal-title":"Lancet."},{"issue":"4","key":"1066_CR14","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jinf.2020.12.023","volume":"82","author":"AT Hanrath","year":"2021","unstructured":"Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect. 2021;82(4):e29\u201330.","journal-title":"J Infect."},{"key":"1066_CR15","doi-asserted-by":"crossref","unstructured":"Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021;35 May 1 [cited 2021 Oct 23]. Available from: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(21)00141-3\/fulltext.","DOI":"10.1016\/j.eclinm.2021.100861"},{"issue":"10280","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","volume":"397","author":"CH Hansen","year":"2021","unstructured":"Hansen CH, Michlmayr D, Gubbels SM, M\u00f8lbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet. 2021;397(10280):1204\u201312.","journal-title":"The Lancet."},{"issue":"54","key":"1066_CR17","doi-asserted-by":"publisher","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","volume":"5","author":"GE Hartley","year":"2020","unstructured":"Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5(54):eabf8891.","journal-title":"Sci Immunol."},{"issue":"6549","key":"1066_CR18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1126\/science.abh1282","volume":"372","author":"CJ Reynolds","year":"2021","unstructured":"Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372(6549):1418\u201323.","journal-title":"Science."},{"issue":"6","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395\u2013404.","journal-title":"Nat Rev Immunol."},{"key":"1066_CR20","unstructured":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals: Cell Reports Medicine [Internet]. [cited 2021 Oct 23]. Available from: https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(21)00204-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379121002044%3Fshowall%3Dtrue."},{"issue":"7889","key":"1066_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","volume":"600","author":"E Andreano","year":"2021","unstructured":"Andreano E, Paciello I, Piccini G, Manganaro N, Pileri P, Hyseni I, et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature. 2021;600(7889):530\u20135.","journal-title":"Nature."},{"key":"1066_CR22","doi-asserted-by":"crossref","unstructured":"Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;17(68):eabn8014.","DOI":"10.1126\/sciimmunol.abn8014"},{"key":"1066_CR23","unstructured":"SARS-CoV-2 variants of concern as of 7 April 2022 [Internet]. European Centre for Disease Prevention and Control. [cited 2022 Apr 13]. Available from: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern."},{"key":"1066_CR24","unstructured":"CoVariants: Per Country [Internet]. [cited 2022 Apr 13]. Available from: https:\/\/covariants.org\/per-country."},{"issue":"7871","key":"1066_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276\u201380.","journal-title":"Nature."},{"key":"1066_CR26","doi-asserted-by":"crossref","unstructured":"Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022; Mar 18 [cited 2022 Apr 13]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0092867422003294.","DOI":"10.1101\/2022.01.25.22269794"},{"key":"1066_CR27","first-page":"1","volume":"6","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;6:1\u20136.","journal-title":"Nature."},{"key":"1066_CR28","doi-asserted-by":"crossref","unstructured":"Yu J, Collier Aris Y, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022;386(16):1579\u201380.","DOI":"10.1056\/NEJMc2201849"},{"issue":"7898","key":"1066_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657\u201363.","journal-title":"Nature."},{"issue":"7821","key":"1066_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2488-1","volume":"584","author":"E Lavezzo","year":"2020","unstructured":"Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo\u2019. Nature. 2020;584(7821):425\u20139.","journal-title":"Nature."},{"issue":"3","key":"1066_CR31","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045.","journal-title":"Eurosurveillance."},{"key":"1066_CR32","unstructured":"SARS-CoV-2 Immunoassay | Abbott Core Laboratory [Internet]. [cited 2021 Oct 26]. Available from: https:\/\/www.corelaboratory.abbott\/us\/en\/offerings\/segments\/infectious-disease\/sars-cov-2."},{"key":"1066_CR33","unstructured":"DiaSorin\u2019s LIAISON\u00ae SARS-CoV-2 Diagnostic Solutions | DiaSorin [Internet]. [cited 2021 Oct 26]. Available from: https:\/\/www.diasorin.com\/en\/immunodiagnostic-solutions\/clinical-areas\/infectious-diseases\/covid-19."},{"key":"1066_CR34","unstructured":"Elecsys\u00ae Anti-SARS-CoV-2 [Internet]. [cited 2021 Oct 26]. Available from: https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/elecsys-anti-sars-cov-2.html."},{"key":"1066_CR35","unstructured":"Tracking SARS-CoV-2 variants [Internet]. [cited 2022 Apr 13]. Available from: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants."},{"issue":"4","key":"1066_CR36","doi-asserted-by":"publisher","first-page":"115403","DOI":"10.1016\/j.diagmicrobio.2021.115403","volume":"100","author":"A Schallier","year":"2021","unstructured":"Schallier A, De Baets S, De Bruyne D, Dauwe K, Herpol M, Couck P. Assay dependence of long-term kinetics of SARS-CoV-2 antibodies. Diagn Microbiol Infect Dis. 2021;100(4):115403.","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"3","key":"1066_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/infdis\/jiaa659","volume":"223","author":"F Muecksch","year":"2021","unstructured":"Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis. 2021;223(3):389\u201398.","journal-title":"J Infect Dis."},{"issue":"5","key":"1066_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jinf.2021.03.015","volume":"82","author":"RJ Harris","year":"2021","unstructured":"Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162\u20139.","journal-title":"J Infect."},{"key":"1066_CR39","doi-asserted-by":"crossref","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829.","DOI":"10.1126\/science.abm0829"},{"issue":"6529","key":"1066_CR40","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.","journal-title":"Science."},{"key":"1066_CR41","doi-asserted-by":"crossref","unstructured":"Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections [Internet]. 2021 Aug [cited 2021 Oct 23] p. 2021.08.24.21262415. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.08.24.21262415v1.","DOI":"10.1101\/2021.08.24.21262415"},{"issue":"7855","key":"1066_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616\u201322.","journal-title":"Nature."},{"issue":"58","key":"1066_CR43","doi-asserted-by":"publisher","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination. Sci Immunol. 2021;6(58):eabi6950.","journal-title":"Sci Immunol."},{"issue":"14","key":"1066_CR44","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1001\/jama.2021.3341","volume":"325","author":"S Saadat","year":"2021","unstructured":"Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325(14):1467\u20139.","journal-title":"JAMA."},{"key":"1066_CR45","first-page":"1","volume":"7","author":"A Cho","year":"2021","unstructured":"Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, et al. Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination. Nature. 2021;7:1\u20139.","journal-title":"Nature."},{"key":"1066_CR46","unstructured":"CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Oct 23]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/delta-variant.html."},{"issue":"6","key":"1066_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med. 2022;386(6):599\u2013601.","journal-title":"N Engl J Med."},{"issue":"3","key":"1066_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","volume":"28","author":"H Gruell","year":"2022","unstructured":"Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022;28(3):477\u201380.","journal-title":"Nat Med."},{"issue":"3","key":"1066_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","volume":"28","author":"PR Wratil","year":"2022","unstructured":"Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med. 2022;28(3):496\u2013503.","journal-title":"Nat Med."},{"issue":"7","key":"1066_CR50","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med."},{"key":"1066_CR51","first-page":"1","volume":"24","author":"Z Liu","year":"2022","unstructured":"Liu Z, Chan JFW, Zhou J, Wang M, Wang Q, Zhang G, et al. A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res. 2022;24:1\u20133.","journal-title":"Cell Res."},{"key":"1066_CR52","unstructured":"Manuto, Laura. Vo-Serology. Github. https:\/\/github.com\/MedCompUnipd\/Vo-Serology (2022)."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01066-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:05:48Z","timestamp":1654855548000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01066-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01066-2","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the serosurveys of the Vo\u2019 population were approved by the Ethics Committee for Clinical Research of the province of Padova (May 2020 survey approved on 30th April 2020, protocol number 0026971; November 2020 survey and additional follow up approved on 11th November 2020, protocol number 0068830). Study participation was by written informed consent. For participants under 18 years of age, consent was provided by a parent or legal guardian. The research conforms to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}